Translation of "use limited " (English → French) :

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

field-of-use restriction [ field of use restriction | field-of-use limitation | field of use limitation ]

exclusive use common elements | exclusive use common property | limited common elements | limited common property

Committee on the Peaceful Uses of the Sea-Bed and the Ocean Floor beyond the Limits of National Jurisdiction [ Sea-Bed Committee | Ad Hoc Committee to Study the Peaceful Uses of the Sea-Bed and the Ocean Floor beyond the Limits of National Jurisdiction ]

exclusive use common elements [ exclusive use common property | limited common elements | limited common property ]

product claim limited to a specific use | use-bound product claim

substance protection limited to a specific use | use-bound substance protection

Definition: A specific developmental disorder in which the child's ability to use expressive spoken language is markedly below the appropriate level for its mental age, but in which language comprehension is within normal limits. There may or may not be abnormalities in articulation. | Developmental dysphasia or aphasia, expressive type

limitation of use of information and material provided

Definition: This category should be used when two or more psychoactive substances are known to be involved, but it is impossible to assess which substance is contributing most to the disorders. It should also be used when the exact identity of some or even all the psychoactive substances being used is uncertain or unknown, since many multiple drug users themselves often do not know the details of what they are taking. | misuse of drugs NOS

A payment instrument should be considered to be used within such a limited network if it can be used only in the following circumstances: first, for the purchase of goods and services in a specific retailer or specific retail chain, where the entities involved are directly linked by a commercial agreement which for example provides for the use of a single payment brand and that payment brand is used at the points of sale and appears, where feasible, on the payment instrument that can be used there; second, for the purchase of a very limited range of goods or s ...[+++]ervices, such as where the scope of use is effectively limited to a closed number of functionally connected goods or services regardless of the geographical location of the point of sale; or third, where the payment instrument is regulated by a national or regional public authority for specific social or tax purposes to acquire specific goods or services.

(a) establishing a Schedule I listing waterways on which the use of personal watercraft is prohibited; (b) establishing a Schedule II listing waterways on which the use of personal watercraft is subject to prescribed restrictions and specifying the prescribed restrictions applicable to each waterway; (c) prescribing restrictions on the use of personal watercraft that may be made applicable to the waterways listed in Schedule II, including, but without limiting the generality of the foregoing, speed limits, restricted hours of operation and limits respecting operating distances from the shoreline; (d) exempting from the application of ...[+++]the regulations or from any of the prohibitions set out in section 9 those law enforcement officers, environment or wildlife officers, persons providing for safety in connection with an activity on the water and other persons acting in the public interest who, in the opinion of the Minister, should be exempted; and (e) generally, for carrying out the purposes and provisions of this Act.

(a) establishing a Schedule I listing waterways on which the use of personal watercraft is forbidden; (b) establishing a Schedule II listing waterways on which the use of personal watercraft is subject to prescribed restrictions and specifying the prescribed restrictions applicable to each waterway; (c) prescribing restrictions on the use of personal watercraft that may be made applicable to the waterways listed in Schedule II, including, but without limiting the generality of the foregoing, speed limits, prohibitions against hours of operation and limits respecting approaching the shoreline; (d) exempting from the regulations those l ...[+++]aw enforcement officers, environment or wildlife officers, persons providing for safety in connection with an activity on the water and other persons acting in the public interest, who, in the opinion of the Minister should be exempted; and (e) generally, for carrying out the purposes and provisions of this Act.

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) what is the cost of developing the system, broken down by costs to date; (d) how much money did the Can ...[+++]adian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...